CMS Open Payments · Program Year 2024
Synthes GmbH
Synthes GmbH reported $2,454,298.25 across General Payments, Research, and Ownership to 2,666 physicians and teaching hospitals across 2,666 transactions.
- $2.5M
- All-tracks total
- 2,666
- Transactions
- 2,666
- Recipients
- −$346.7K
- General Payments vs PY2023
Synthes GmbH reported $2,454,298.25 across all CMS Open Payments tracks (General + Research + Ownership) to 2,666 physicians and teaching hospitals in Program Year 2024 - ranking #407 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,454,298.25, averaging $920.59 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer synthes-gmbh Synthes GmbH
$2.5M · #407/1,925 · 0.0% industry · PY2024
- TOT $2.5M
- RANK #407
- SHARE 0.0%
- TXN 2,666
- RCP 2,666
- CAT 4
- GEN $2.5M
- ΔGEN −$346.7K
- TOP1 7.1%
- PY 2024
Volume peers
Nearest volume peer: AstraZeneca AB ($2.5M)
Synthes GmbH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Synthes GmbH's CMS-reported General Payments decreased by $346.7K (−12.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SYNTHES GMBHPY2023: SYNTHES GMBHPY2024: Synthes GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,801,022.65
- PY2024
- $2,454,298.25
What the Data Shows for Synthes GmbH
Averaging $920.59 per transaction and $920.59 per recipient, Synthes GmbH's Program Year 2024 total comes to $2,454,298.25 across 2,666 transactions and 2,666 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #407 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
680 transactions worth $944.1K make "Compensation for Faculty or Speaker (Medical Education)" the top general-payment category in the 4-category breakdown below, 38.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Synthes GmbH's largest category was "Compensation for Faculty or Speaker (Medical Education)" at $944.1K - 38.5% of General Payments.
Synthes GmbH reports 4 general-payment categories - the top three are Compensation for Faculty or Speaker (Medical Education) (38.5%), Travel and Lodging (34.3%), and Grant (25.2%). The remaining 1 category make up 2.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Synthes GmbH divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Faculty or Speaker (Medical Education) | $944.1K | 680 | 38.5% |
| Travel and Lodging | $841.6K | 1,564 | 34.3% |
| Grant | $619.0K | 52 | 25.2% |
| Food and Beverage | $49.7K | 370 | 2.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $386,539.95 (15.7%) of $2,454,298.25 in this company's General Payments records across 596 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Synthes GmbH
The five named recipients with the highest reported General Payments from this company
- 1
University Of Washington Med Ctr
$173,039.95 across 15 reported transactions
- 2
University Of Alabama Hospital
$74,500.00 across 8 reported transactions
- 3
U Of U Hospitals & Clinics
$52,500.00 across 3 reported transactions
- 4
Rush University Medical Center
$43,500.00 across 2 reported transactions
- 5
Cedars-Sinai Medical Center
$43,000.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Synthes GmbH's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Synthes GmbH.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Synthes GmbH.
Showing 6 of 1,924 companies with CMS-reported payment data.
Saluda Medical Americas, Inc.
DePuy Synthes Sales Inc.
Otsuka Pharmaceutical Co., Ltd.
CoapTech, Inc.
Tolmar, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.